In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who had not been treated with cholesterol lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.

Inclusion Criteria:

• patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C 3.2 mmol/l.
• According to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention.
• The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation.
• Patient approved to place anonymous results at the disposal of AstraZeneca

Exclusion Criteria:

• Patients with symptoms of myalgia, myopathy or liver function insufficiency (including raised serum transaminases) which bear a causal relation to the treatment with statins, patients with familiar dyslipidemia and/or patients with contra-indications for treatment with rosuvastatin

patients of practices of General Practioners